The andrographis herb, a member of the Acanthaceae family, continues to gain recognition for its medicinal properties. Commonly known as green chiretta, Andrographis paniculata originates from India and Sri Lanka and thrives across Southern and Southeast Asia. This herbal extract serves as an alternative therapeutic remedy for various ailments, ranging from severe chronic diseases to common flu. By enhancing immunity and promoting overall health, andrographis herb plays a crucial role in traditional medicine. Beyond pharmaceuticals, industries utilize it for food preservation, livestock growth, and as a dietary supplement to boost nutritional value.
As awareness of the medicinal benefits of andrographis herb grows, healthcare professionals increasingly incorporate it into treatment practices. This rising adoption is expected to drive demand from 2025 to 2035.
Andrographis herb has proven so potent that it played a key role in managing symptoms of one of the deadliest viruses in history. The COVID-19 pandemic forced the medical community to explore alternative treatment options, including herbal remedies.
In 2025, researchers expanded their studies on Andrographis paniculata, revealing its potential to treat respiratory infections and inflammatory diseases. Governments and health organizations worldwide have continued to endorse its usage. The health ministry of Thailand had previously approved andrographis extract in December 2020 to reduce COVID-19 severity and lower treatment costs. By 2025, additional research validated its effectiveness, prompting increased acceptance in both traditional and modern medicine.
A shift toward herbal and ayurvedic medicines has further boosted the andrographis herb market, unlocking new revenue opportunities for producers.
In March 2026, Thailand’s government announced initiatives to accelerate exports of Thai black ginger, turmeric, and andrographis herb to neighboring Southeast Asian nations for medicinal and topical applications. Authorities labeled these products as "Herbal Champions" to emphasize their economic and therapeutic value. The herbal industry witnessed significant growth in response to this initiative.
In December 2027, Doi Kham, a leading Thai herbal company, reported a 50% revenue surge from its herbal product segment. Encouraged by this success, the company expanded its offerings to include a new extract derived from 'fah talai jone' (Andrographis paniculata), also known as the "king of bitters."
Ongoing research into the andrographis herb’s effectiveness against various ailments, fueled by rising demand for herbal and traditional medicine, is expected to open new doors for suppliers over the next decade. However, concerns over regulatory compliance and potential misuse may pose challenges if not addressed properly.
The rising prevalence of drug-resistant infections, limitations on synthetic antioxidant drugs, and antibiotic side effects have revived interest in herbal alternatives. Scientists continue exploring medicinal herbs to develop safe and effective treatments. Andrographis herb remains a top recommendation for stomachic, hepatoprotective, dyspepsia, anthelmintic, and febrifuge applications. With potential use in at least 27 Ayurvedic medicines and as a fragrance and flavoring agent in food, its market prospects appear promising.
Market analysts segment the andrographis herb extract industry into pharmaceuticals, food service, dietary supplements, and other applications. Its broad-spectrum medicinal applications indicate high market potential. While primarily used in Asia, the herb is poised to enter mainstream global markets due to rising demand for dietary supplements and herbal medicines. Companies such as Bioprex Labs, Kisalaya Herbals Limited, Konark Herbals and Health Care, and Perennial Life Sciences Pvt. Ltd. remain key players in this expanding industry.
